AKT1 and Cognitive impairment: The effects of chronic liraglutide administration (subcutaneous; 300 μg/kg/day for 28 days) were investigated on depressive-like phenotypes, cognitive deficits, and hippocampal phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt)/mechanistic target of rapamycin (mTOR)-regulated autophagy.